

# Sine Reker Hadrup

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5237512/publications.pdf>

Version: 2024-02-01

97  
papers

9,461  
citations

53794

45  
h-index

42399

92  
g-index

107  
all docs

107  
docs citations

107  
times ranked

14488  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016, 351, 1463-1469.	12.6	2,445
2	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14.	28.9	485
3	Longitudinal Studies of Clonally Expanded CD8 T Cells Reveal a Repertoire Shrinkage Predicting Mortality and an Increased Number of Dysfunctional Cytomegalovirus-Specific T Cells in the Very Elderly. <i>Journal of Immunology</i> , 2006, 176, 2645-2653.	0.8	447
4	Neoantigen landscape dynamics during human melanoma T cell interactions. <i>Nature</i> , 2016, 536, 91-95.	27.8	387
5	Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. <i>Nature Protocols</i> , 2006, 1, 1120-1132.	12.0	293
6	Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. <i>Nature Methods</i> , 2009, 6, 520-526.	19.0	286
7	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. <i>Nature Biotechnology</i> , 2016, 34, 1037-1045.	17.5	279
8	Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. <i>Cancer Microenvironment</i> , 2013, 6, 123-133.	3.1	263
9	Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cell-Associated Epitopes Using Combinatorial MHC Multimers. <i>Diabetes</i> , 2010, 59, 1721-1730.	0.6	187
10	SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8 <sup>+</sup> T cell activation in COVID-19 patients. <i>Science Immunology</i> , 2021, 6, .	11.9	183
11	MuPeXI: prediction of neo-epitopes from tumor sequencing data. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1123-1130.	4.2	177
12	TIL therapy broadens the tumor-reactive CD8 <sup>+</sup> T cell compartment in melanoma patients. <i>Oncotarget</i> , 2012, 1, 409-418.	4.6	171
13	High-throughput identification of antigen-specific TCRs by TCR gene capture. <i>Nature Medicine</i> , 2013, 19, 1534-1541.	30.7	166
14	Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3825-3830.	7.1	150
15	Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. <i>Nature Medicine</i> , 2019, 25, 1549-1559.	30.7	147
16	Dissection of T-cell Antigen Specificity in Human Melanoma. <i>Cancer Research</i> , 2012, 72, 1642-1650.	0.9	137
17	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. <i>Journal of Translational Medicine</i> , 2012, 10, 169.	4.4	134
18	Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. <i>Nature Protocols</i> , 2012, 7, 891-902.	12.0	131

#	ARTICLE	IF	CITATIONS
19	Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1791-1804.	4.2	103
20	An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes. <i>Frontiers in Immunology</i> , 2017, 8, 1566.	4.8	103
21	Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. <i>Blood</i> , 2011, 117, 2200-2210.	1.4	101
22	NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCR $\alpha$ and $\beta$ sequence data. <i>Communications Biology</i> , 2021, 4, 1060.	4.4	101
23	T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes. <i>Nature Biotechnology</i> , 2018, 36, 1191-1196.	17.5	85
24	Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells. <i>Journal of the American Chemical Society</i> , 2009, 131, 9695-9703.	13.7	84
25	Identification of Novel Survivin-Derived CTL Epitopes with Different HLA-A-Restriction Profiles. <i>Cancer Biology and Therapy</i> , 2004, 3, 173-179.	3.4	81
26	T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors. <i>Clinical Cancer Research</i> , 2014, 20, 1768-1778.	7.0	81
27	CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. <i>Nature Communications</i> , 2019, 10, 837.	12.8	80
28	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. <i>Nature Cancer</i> , 2020, 1, 546-561.	13.2	74
29	Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. <i>Seminars in Cancer Biology</i> , 2003, 13, 449-459.	9.6	73
30	Immunogenicity of Constitutively Active V599EBRaf. <i>Cancer Research</i> , 2004, 64, 5456-5460.	0.9	71
31	Lipid Nanoparticles for Delivery of Therapeutic RNA Oligonucleotides. <i>Molecular Pharmaceutics</i> , 2019, 16, 2265-2277.	4.6	69
32	5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. <i>Blood Cancer Journal</i> , 2014, 4, e197-e197.	6.2	67
33	Thinking Outside the Gate: Single-Cell Assessments in Multiple Dimensions. <i>Immunity</i> , 2015, 42, 591-592.	14.3	67
34	Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. <i>Cytotherapy</i> , 2010, 12, 721-734.	0.7	66
35	Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. <i>Journal of Autoimmunity</i> , 2011, 37, 151-159.	6.5	66
36	Evolution of MHC-based technologies used for detection of antigen-responsive T cells. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 657-666.	4.2	65

#	ARTICLE	IF	CITATIONS
37	Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells. <i>Science Immunology</i> , 2019, 4, .	11.9	64
38	The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase. <i>PLoS ONE</i> , 2009, 4, e6910.	2.5	64
39	Human endogenous retroviruses and their implication for immunotherapeutics of cancer. <i>Annals of Oncology</i> , 2018, 29, 2183-2191.	1.2	63
40	Immunogenicity of Bcl-2 in patients with cancer. <i>Blood</i> , 2005, 105, 728-734.	1.4	60
41	T-cell Responses in the Microenvironment of Primary Renal Cell Carcinomaâ€”Implications for Adoptive Cell Therapy. <i>Cancer Immunology Research</i> , 2018, 6, 222-235.	3.4	59
42	Discovering naturally processed antigenic determinants that confer protective T cell immunity. <i>Journal of Clinical Investigation</i> , 2013, 123, 1976-1987.	8.2	58
43	Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. <i>Nature Communications</i> , 2020, 11, 5660.	12.8	55
44	Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	54
45	PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5779-5788.	7.0	53
46	High-Throughput T-Cell Epitope Discovery Through MHC Peptide Exchange. <i>Methods in Molecular Biology</i> , 2009, 524, 383-405.	0.9	52
47	HLA-B35-restricted immune responses against survivin in cancer patients. <i>International Journal of Cancer</i> , 2004, 108, 937-941.	5.1	51
48	Conditional ligands for $\alpha$ CD8 <sup>+</sup> T cell responses in acute and chronic viral diseases. <i>European Journal of Immunology</i> , 2013, 43, 1109-1120.	2.9	49
49	Immune Mechanisms in Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2016, 17, 944.	4.1	48
50	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN $\gamma$ Signaling. <i>Cancer Research</i> , 2017, 77, 4562-4566.	0.9	39
51	Spontaneous Immunity against Bcl-xL in Cancer Patients. <i>Journal of Immunology</i> , 2005, 175, 2709-2714.	0.8	38
52	Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. <i>International Journal of Cancer</i> , 2006, 119, 831-838.	5.1	38
53	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	12.8	37
54	High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations. <i>PLoS ONE</i> , 2011, 6, e22523.	2.5	36

#	ARTICLE	IF	CITATIONS
55	The Melanoma Inhibitor of Apoptosis Protein: A Target for Spontaneous Cytotoxic T Cell Responses. <i>Journal of Investigative Dermatology</i> , 2004, 122, 392-399.	0.7	35
56	MHC-based detection of antigen-specific CD8+ T cell responses. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1425-1433.	4.2	29
57	The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. <i>Immunogenetics</i> , 2000, 52, 107-111.	2.4	27
58	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. <i>Frontiers in Immunology</i> , 2020, 11, 373.	4.8	27
59	T Cell Epitope Prediction and Its Application to Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 712488.	4.8	27
60	Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 27062-27074.	1.8	26
61	Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. <i>Leukemia</i> , 2005, 19, 2273-2280.	7.2	25
62	Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e23288.	4.6	25
63	Persistence of survivin specific T cells for seven years in a melanoma patient During complete remission. <i>Cancer Biology and Therapy</i> , 2006, 5, 480-482.	3.4	24
64	Fundamental immune“oncogenicity trade-offs define driver mutation“fitness. <i>Nature</i> , 2022, 606, 172-179.	27.8	23
65	High frequency of T cells specific for cryptic epitopes in melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e25374.	4.6	21
66	Design and validation of conditional ligands for <sc>HLA“B</sc>*08:01, <sc>HLA“B</sc>*15:01, <sc>HLA“B</sc>*35:01, and <sc>HLA“B</sc>*44:05. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 967-975.	1.5	21
67	Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 37-48.	1.5	19
68	Preclinical evaluation of NF-“B-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 451-464.	3.2	18
69	T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation. <i>Immuno-Oncology Technology</i> , 2019, 2, 1-10.	0.3	18
70	Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF“09b, in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2022, 11, 2023255.	4.6	18
71	Spontaneous T-cell responses against peptides derived from the Taxol resistance“associated gene-3 (TRAG-3) protein in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 219-228.	4.2	15
72	CD8 T-cell Responses against Cyclin B1 in Breast Cancer Patients with Tumors Overexpressing p53. <i>Clinical Cancer Research</i> , 2009, 15, 1543-1549.	7.0	15

#	ARTICLE	IF	CITATIONS
73	Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2013, 12, 309-31.	0.6	12
74	A user's guide to multicolor flow cytometry panels for comprehensive immune profiling. <i>Analytical Biochemistry</i> , 2021, 627, 114210.	2.4	12
75	Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1221-1231.	4.2	11
76	Determining T-cell specificity to understand and treat disease. <i>Nature Biomedical Engineering</i> , 2017, 1, 784-795.	22.5	10
77	Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 858.	4.8	9
78	T cell recognition of novel shared breast cancer antigens is frequently observed in peripheral blood of breast cancer patients. <i>Oncimmunology</i> , 2019, 8, e1663107.	4.6	9
79	Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 527-533.	4.2	8
80	Broadening the repertoire of melanoma-associated T-cell epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 609-620.	4.2	8
81	Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome—A phase I clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 433-444.	4.2	8
82	Novel Molecular Targets for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 140.	3.7	8
83	Concomitant Administration of Interleukin-2 During Therapeutic Vaccinations Against Cancer: The Good, the Bad, or the Evil?. <i>Journal of Clinical Oncology</i> , 2005, 23, 5265-5267.	1.6	6
84	Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. <i>Human Immunology</i> , 2008, 69, 266-272.	2.4	6
85	Prediction of neoepitopes from murine sequencing data. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 159-161.	4.2	6
86	The antigen specific composition of melanoma tumor infiltrating lymphocytes?. <i>Oncimmunology</i> , 2012, 1, 935-936.	4.6	5
87	Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1.	4.2	5
88	Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer. <i>Journal of Investigative Dermatology</i> , 2022, 142, 239-243.e13.	0.7	3
89	Immune Risk Phenotypes and Associated Parameters in Very Old Humans: A Review of Findings in the Swedish NONA Immune Longitudinal Study. , 2007, , 1-14.		3
90	Natural T-cell responses against minor histocompatibility antigen (mHag) HY following HLA-matched hematopoietic cell transplantation: what are the requirements for a "good" mHag?. <i>Leukemia</i> , 2008, 22, 1948-1951.	7.2	2

#	ARTICLE	IF	CITATIONS
91	Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709). <i>Cytotherapy</i> , 2009, 11, 631-641.	0.7	2
92	Discovery of CD8 T cell epitopes in Merkel cell polyomavirus through combinatorial encoding with MHC multimers. , 2013, 1, P13.		2
93	Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
94	Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma. , 2013, 1, .		0
95	Comment on "5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity": <i>Mediators of Inflammation</i> , 2015, 2015, 1-3.	3.0	0
96	Optimization in Detection of Antigen-Specific T Cells Through Differentially Labeled MHC Multimers. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 955-964.	1.5	0
97	Antigen-specific T cells. , 2022, , 193-208.		0